Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14093037 | 1.00 | NCF1 (0.37) | NCF1ATML3MBTL1CYP2D6KCNH2 | |
| SCHEMBL11989609 | 1.00 | NCF1 (0.37) | NCF1ATML3MBTL1CYP2D6KCNH2 | |
| SCHEMBL18923903 | 0.85 | ATM (0.49) | NCF1ATML3MBTL1CYP2D6KCNH2 | |
| SCHEMBL2612760 | 0.85 | ATM (0.49) | NCF1ATML3MBTL1CYP2D6KCNH2 | |
| SCHEMBL6784593 | 0.85 | ATM (0.49) | NCF1ATML3MBTL1CYP2D6KCNH2 | |
| SCHEMBL179337 | 0.83 | NCF1 (0.40) | NCF1CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL17148645 | 0.83 | ATM (0.43) | ATML3MBTL1CYP2D6KCNH2CYP1A2 | |
| SCHEMBL90573 | 0.80 | NCF1 (0.39) | NCF1ATML3MBTL1 | |
| SCHEMBL13713126 | 0.80 | ATM (0.41) | NCF1ATML3MBTL1CYP1A2 | |
| SCHEMBL24907047 | 0.80 | NCF1 (0.31) | NCF1ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20230399309-A1 | DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Guangzhou Yufan Nantu Biotechnologies Co., Ltd (CN) | 2023-12-14 | — | — | US | disclosed |
| US-11834451-B2 | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20080261970-A1 | Sufonamides and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-09-18 | — | — | US | disclosed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-12-27 | — | — | US | disclosed |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC5 | NCF1 637/4885ATM 1953/4885L3MBTL1 1578/4885 |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | NCF1 4322/4885ATM 3587/4885L3MBTL1 4829/4885 |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | NCF1 709/4885ATM 2118/4885L3MBTL1 2445/4885 |
| US-20230399309-A1 | DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, VRK1 | NCF1 2452/4885ATM 2022/4885L3MBTL1 2017/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | NCF1 2576/4885ATM 242/4885L3MBTL1 3738/4885 |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | AHR, CD274, ARNT | NCF1 1891/4885ATM 1726/4885L3MBTL1 1696/4885 |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | NCF1 1297/4885ATM 1600/4885L3MBTL1 2704/4885 |
| US-20070191333-A1 | Antibacterial agents | MRPL21, RPN2, FBL | NCF1 254/4885ATM 3958/4885L3MBTL1 4527/4885 |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | NCF1 709/4885ATM 2118/4885L3MBTL1 2445/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | NCF1 2466/4885ATM 4765/4885L3MBTL1 4819/4885 |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | NCF1 709/4885ATM 2118/4885L3MBTL1 2445/4885 |
| US-20070270473-A1 | Sulfonamide Compounds and Uses Thereof | GHSR, GHRHR, SSTR2 | NCF1 3593/4885ATM 3323/4885L3MBTL1 4774/4885 |
| US-20080261970-A1 | Sufonamides and Uses Thereof | CYP21A2, LPXN, OAT | NCF1 1643/4885ATM 4272/4885L3MBTL1 2377/4885 |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | NCF1 3043/4885ATM 1067/4885L3MBTL1 4555/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NCF1 1349/4885ATM 3957/4885L3MBTL1 3066/4885 |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | HTR5A, GRM5, TAAR5 | NCF1 3646/4885ATM 4156/4885L3MBTL1 2611/4885 |
| US-11834451-B2 | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | GTF3C3, VDAC3, GTF3C5 | NCF1 1715/4885ATM 4452/4885L3MBTL1 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.